SequelSEC

Vireo Growth Inc. VREOF

Pharmaceutical Preparations · CIK 0001771706 · Fiscal year ends 1231

Revenue
$511.67M
Fiscal year ended 2026-06-30
Operating income
$1.69M
Fiscal year ended 2026-06-30
Free cash flow
-$116.31M
Fiscal year ended 2026-06-30

Vireo Growth Inc. (VREOF) reported revenue of $511.67M and net income of -$67.07M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Vireo Growth Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Vireo Growth Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$511.67M
Cost of revenueUnavailable
Gross profit$248.87M
Operating income$1.69M
Net income-$67.07M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$15.00M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$167.86M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Vireo Growth Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalentsUnavailable
Total assets$1.27B
Current assets$394.50M
Total liabilities$831.20M
Current liabilities$390.70M
Total equity incl. NCI$442.50M
Temporary (mezzanine) equityUnavailable
Inventory$149.40M
Accounts receivableUnavailable
Goodwill$161.10M
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Vireo Growth Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$26.21M
Capital expenditures$142.52M
Investing cash flow-$85.84M
Financing cash flow$76.22M
Net change in cashUnavailable
Stock-based compensation$27.55M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$24.11M

Derived

Vireo Growth Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$116.31M
Gross margin48.6%
Operating margin0.3%
FCF margin-22.7%
SBC / revenue5.4%
Current ratio1.01x
Revenue YoY growth316.7%
Net margin-13.1%
R&D / revenueUnavailable
CapEx / revenue27.9%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VREOF in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-17View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.